Sensei Biotherapeutics (HAM:407) Short-Term Capital Lease Obligation : €2.28 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Sensei Biotherapeutics Short-Term Capital Lease Obligation?

Sensei Biotherapeutics's Short-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was €2.28 Mil.

Sensei Biotherapeutics's quarterly Short-Term Capital Lease Obligation declined from Sep. 2023 (€2.25 Mil) to Dec. 2023 (€2.24 Mil) but then increased from Dec. 2023 (€2.24 Mil) to Mar. 2024 (€2.28 Mil).

Sensei Biotherapeutics's annual Short-Term Capital Lease Obligation increased from Dec. 2021 (€0.60 Mil) to Dec. 2022 (€2.01 Mil) and increased from Dec. 2022 (€2.01 Mil) to Dec. 2023 (€2.24 Mil).

Sensei Biotherapeutics Short-Term Capital Lease Obligation Historical Data

The historical data trend for Sensei Biotherapeutics's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sensei Biotherapeutics Short-Term Capital Lease Obligation Chart

Sensei Biotherapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.03

0.60

2.01

2.24

Sensei Biotherapeutics Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															2.13	2.14	2.25	2.24	2.28

Sensei Biotherapeutics Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Sensei Biotherapeutics Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Sensei Biotherapeutics's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Sensei Biotherapeutics (HAM:407) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sensei Biotherapeutics Inc (HAM:407) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

SNSE:USA 407:Germany

Address

1405 Research Boulevard, Suite 710, Boston, MA, USA, 02210

Website

https://www.senseibio.com

Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. The company currently has three investigational products. 1) SNS-101 is a conditionally active monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T-cell activation): 2) SNS-102 is a conditionally active monoclonal antibody targeting VSIG4 (V-Set and Immunoglobulin Domain Containing 4), an immune checkpoint often expressed on macrophages: 3) SNS-103 is a conditionally active monoclonal antibody targeting ENTPDase1 (ecto-nucleoside triphosphate diphosphohydrolase-1), also known as CD39.

Sensei Biotherapeutics (HAM:407) Headlines

No Headlines